In 2023, the global Treatment-Resistant Depression Treatment Market is anticipated to be worth US$ 1.69 billion. Because of the rising frequency of depression and anxiety disorders in adults, as well as the ageing population, the global demand for treatment-resistant depression treatment is expected to expand at a C.
/PRNewswire/ Major players in the rituximab biosimilars market are Pfizer Inc., Mylan Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Celltrion.